Florida Hall E
6000 W Osceola Pkwy
Kissimmee, FL 34746
7:00 - 7:10 AM: Welcome and Introduction
7:10 - 7:30 AM: The Impact of Novel Therapies on HCT in Myeloma
7:30 - 7:50 AM: Selecting Optimal Treatment in Post-HCT Relapsed Disease
7:50 - 8:00 AM: Symposium Summary and Audience Q&A
The recent emergence and validation of novel and next-generation therapeutics, such as proteasome inhibitors, immunomodulators, immunotherapies, and epigenetic agents, have changed optimal practice in the management of multiple myeloma. As the science continues to evolve, clinicians now have the opportunity to translate this evidence into daily practice; when used in patients eligible for autologous hematopoietic stem cell transplantation (HCT), novel therapies have the potential to dramatically improve outcomes with more potent and personalized induction and consolidation/maintenance regimens; subsequently, a greater role for the novel therapeutics is being realized for patients with relapsed disease, including in patients already treated with HCT. This breakfast symposium will feature expert insights on the management of transplant-eligible patients with myeloma, including the role of innovative therapies and considerations for selection of optimal treatment prior to and after HCT.
Upon completion of this activity, participants should be better able to:
This activity will be designed to meet the educational needs of hematologist-oncologists, oncologists, BMT specialists, BMT nurse specialists, and other clinicians involved in the care of patients with myeloma.
In order to receive credit, participants must attend the live activity and complete the request for credit. There are no prerequisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon completion of the request for credit at the end of the post-test and evaluation form.
Release and Expiration Date: February 23, 2017
Time to Complete: 60 minutes
In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Kenneth C. Anderson, MD
Kraft Family Professor of Medicine
Harvard Medical School
Director, Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Shaji Kumar, MD
Professor of Medicine
Division of Hematology
PVI, PeerView Institute for Medical Education
Aarati Ranganathan, PhD
PVI, PeerView Institute for Medical Education
The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
The Medical College of Wisconsin designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CME activity is jointly provided by The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education.
This activity is supported by educational grants from Celgene Corporation, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Karyopharm Therapeutics and Takeda Oncology.
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.
Please visit our other symposia on AML, www.peerviewpress.com/AMLBMT, Fungal Infections, www.peerviewpress.com/infectionsHCT, Hodgkin Lymphoma, www.peerviewpress.com/HL17, and Myelofibrosis, www.peerviewpress.com/MFBMT